Brief: AstraZeneca Says Truqap Approved In US For Prostate Cancer
15/06/2026 07:32
BRIEF-AstraZeneca Says Truqap Approved In US For Prostate Cancer June 15 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA PLC - TRUQAP APPROVED IN US FOR PROSTATE CANCER
ASTRAZENECA PLC - TRUQAP APPROVED IN US FOR PROSTATE CANCER
ASTRAZENECA - FDA APPROVES TRUQAP COMBINATION AS FIRST TARGETED TREATMENT FOR PTEN-DEFICIENT METASTATIC PROSTATE CANCER
Source text: ID:nRSO1983Ia
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains